Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2F | Q9BZM2 | 3/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 18/20 | 0.52 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.45 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632206 | 0.93 | PLA2G1B (0.49) | PLA2G2FPLA2G1BPLA2G2EPLA2G10PLA2G2D | |
| SCHEMBL7193741 | 0.90 | PLA2G1B (0.65) | PLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL13893783 | 0.88 | PLA2G1B (0.55) | PLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL13632227 | 0.88 | PLA2G10 (0.52) | PLA2G2FPLA2G1BPLA2G2EPLA2G10PLA2G2D | |
| SCHEMBL7192239 | 0.87 | PLA2G1B (0.64) | PLA2G2FPLA2G1BPLA2G2EPLA2G10PLA2G2D | |
| SCHEMBL7187184 | 0.86 | PLA2G1B (0.60) | PLA2G2FPLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL13893693 | 0.85 | PLA2G1B (0.67) | PLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL7186945 | 0.85 | PLA2G1B (0.67) | PLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL13893708 | 0.83 | PLA2G1B (0.60) | PLA2G1BPLA2G2EPLA2G2APLA2G5 | |
| SCHEMBL7190902 | 0.82 | PLA2G1B (0.65) | PLA2G1BPLA2G2EPLA2G2APLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286796-A1 | Compounds exhibiting type X sPLA2 inhibiting effect | OGAWA TOMOYUKI | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286796-A1 | Compounds exhibiting type X sPLA2 inhibiting effect | XDH, PLA2G12A, CTRB2 | PLA2G2F 81/4885PLA2G1B 70/4885PLA2G2E 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.